Kisspeptin-10 (KP-10), also known as Metastin(112-121), is a decapeptide derived from the larger kisspeptin protein, which is encoded by the KISS1 gene. It is a key regulator of the reproductive hormonal axis, particularly influencing the release of gonadotropin-releasing hormone (GnRH). KP-10 is synthesized as part of a larger precursor protein and is cleaved to its active form. The structure of KP-10 consists of a sequence of 10 amino acids, making it a relatively small peptide with significant biological activity. Researchers have primarily focused on KP-10's role in reproductive biology and its potential therapeutic applications. It has been observed to stimulate the release of GnRH, thereby influencing the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). These effects have implications for fertility treatments and the management of reproductive disorders. Additionally, KP-10 has been investigated for its role in cancer metastasis, as it was initially discovered in the context of its ability to suppress tumor spread. The mechanism of action of KP-10 involves binding to the G-protein coupled receptor GPR54, also known as the kisspeptin receptor. This interaction triggers a cascade of intracellular signaling pathways that ultimately lead to the release of GnRH from the hypothalamus. The activation of GPR54 is crucial for the initiation of puberty and the maintenance of reproductive function. Pharmacokinetic studies of KP-10 indicate that it has a relatively short half-life, with rapid degradation in the bloodstream. Its stability and bioavailability can vary depending on the route of administration, with subcutaneous and intravenous routes being more effective than oral administration due to poor bioavailability. Current research on KP-10 is focused on its potential therapeutic applications in reproductive health and oncology. However, it is not yet approved as a medicinal product by major regulatory agencies, and its use is primarily confined to research settings.